Lifestyle Interventions for Patients with Non-alcoholic Steato-hepatitis-Design, Rationale and Protocol of the Study "target Group-specific Optimisation of Lifestyle Interventions for Behavior Change in Non-alcoholic Steato-hepatitis (OPTI-NASH)"

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2023 Jul 27

PMID 37498941

Authors

Kathrin Kruger

Carina Oedingen

Achim Kautz

Diane Langenbacher

Siegbert Rossol

Jona T Stahmeyer

Christian Krauth

Affiliations

Soon will be listed here.

Abstract

Background: Non-alcoholic steato-hepatitis (NASH) is the inflammatory, progressive form of non-alcoholic fatty liver disease (NAFLD). A delayed diagnose interval is typical for the majority of the patients because of the asymptomatic natural course. However, serious sequelae may develop such as cirrhosis or hepatocellular carcinoma. NASH is also associated with an increased risk of metabolic diseases. Obesity developed due to a lack of exercise or a disadvantageous diet often leads to NAFLD or NASH, thereby interventions including enhanced physical activity and calorie reduction form the actual gold standard of treatment. To date, patients rarely use these. The project aims to model lifestyle interventions based on the preferences of the NASH patients.

Methods: Based on a systematic review and focus group discussions, two discrete choice experiments (DCE) will be designed, one on aspects influencing successful uptake of lifestyle interventions and one to analyses parameters contributing to long-term participation. An online survey will be used to elicit patient's preferences on program design and on motivational aspects in a cross-sectional design. The recruitment will take place in nine certified specialist practices and hospital outpatient clinics aiming to reach a sample size of n = 500 which is also required for the DCE design.

Discussion: The results will provide an overview of the NASH patient's preferences regarding the successful uptake and long-term implementation of lifestyle interventions. Recommendations for optimized lifestyle change programs will be derived and an intervention manual will be developed to facilitate target group-specific inclusion in programs in practice.

References

de Bekker-Grob E, Hol L, Donkers B, van Dam L, Habbema J, van Leerdam M . Labeled versus unlabeled discrete choice experiments in health economics: an application to colorectal cancer screening. Value Health. 2009; 13(2):315-23. DOI: 10.1111/j.1524-4733.2009.00670.x. View

Miele L, Targher G . Understanding the association between developing a fatty liver and subsequent cardio-metabolic complications. Expert Rev Gastroenterol Hepatol. 2015; 9(10):1243-5. DOI: 10.1586/17474124.2015.1074860. View

Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L . Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015; 149(2):367-78.e5. DOI: 10.1053/j.gastro.2015.04.005. View

Reed Johnson F, Lancsar E, Marshall D, Kilambi V, Muhlbacher A, Regier D . Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013; 16(1):3-13. DOI: 10.1016/j.jval.2012.08.2223. View

Konerman M, Jones J, Harrison S . Pharmacotherapy for NASH: Current and emerging. J Hepatol. 2017; 68(2):362-375. DOI: 10.1016/j.jhep.2017.10.015. View

Estes C, Anstee Q, Arias-Loste M, Bantel H, Bellentani S, Caballeria J . Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018; 69(4):896-904. DOI: 10.1016/j.jhep.2018.05.036. View

Francque S, Marchesini G, Kautz A, Walmsley M, Dorner R, Lazarus J . Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep. 2021; 3(5):100322. PMC: 8514420. DOI: 10.1016/j.jhepr.2021.100322. View

Haftenberger M, Heuer T, Heidemann C, Kube F, Krems C, Mensink G . Relative validation of a food frequency questionnaire for national health and nutrition monitoring. Nutr J. 2010; 9:36. PMC: 2945984. DOI: 10.1186/1475-2891-9-36. View

Cook N, Geier A, Schmid A, Hirschfield G, Kautz A, Schattenberg J . The Patient Perspectives on Future Therapeutic Options in NASH and Patient Needs. Front Med (Lausanne). 2019; 6:61. PMC: 6457207. DOI: 10.3389/fmed.2019.00061. View

10.

. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990; 16(3):199-208. DOI: 10.1016/0168-8510(90)90421-9. View

11.

Marchesini G, Petta S, Dalle Grave R . Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice. Hepatology. 2015; 63(6):2032-43. DOI: 10.1002/hep.28392. View

12.

Roeb E, Canbay A, Bantel H, Bojunga J, de Laffolie J, Demir M . . Z Gastroenterol. 2022; 60(9):1346-1421. DOI: 10.1055/a-1880-2283. View

13.

Bridges J, Hauber A, Marshall D, Lloyd A, Prosser L, Regier D . Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011; 14(4):403-13. DOI: 10.1016/j.jval.2010.11.013. View

14.

Hallsworth K, Adams L . Lifestyle modification in NAFLD/NASH: Facts and figures. JHEP Rep. 2020; 1(6):468-479. PMC: 7005657. DOI: 10.1016/j.jhepr.2019.10.008. View

15.

Ustun T, Chatterji S, Kostanjsek N, Rehm J, Kennedy C, Epping-Jordan J . Developing the World Health Organization Disability Assessment Schedule 2.0. Bull World Health Organ. 2010; 88(11):815-23. PMC: 2971503. DOI: 10.2471/BLT.09.067231. View